bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-20-2190

Order Name:
Apolipoprotein A1

 
Useful For:
Used for the quantitation of apolipoprotein A-I in human serum.

Evaluating risk for atherosclerotic cardiovascular disease.
 
Methodology:
Immunoturbidimetry 
 
AliasesName:
Apo A-1
Apolipoprotein A-1
 
 
 
Test Code:
090-20-2190

Order Name:
Apolipoprotein A1

 
Collection Specimen Or Container:
Blood/ Plain blood (Red top) 6 mL, 1 tube
 
Specimen Testing Type:
Serum, minimum volume 1 mL
 
Sub Mission Container:
Plastic vial
 
Rejection Criteria:
Hemolysis:4+ reject
 
Specimen Stabillity:
Specimen Type Temperature Time
Serum (Keep in original tube) Refrigerated, 2oC to 8oC 8 hours
Serum Refrigerated, 2oC to 8oC 3 days
Frozen, -20oC 2 months
 
 
 
Test Code:
090-20-2190

Order Name:
Apolipoprotein A1

 
Method detail:
Immunoturbidimetry 
 
Schedule:
Tested daily (24 hours)
 
Turnaround Time:
Specimen collected to reported within 2 hours (120 mins)
 
Performing Location:
Chemistry, Laboratory Department Tel. 13224
 
Specimen Retention Time:
5 days
 
 
 
Test Code:
090-20-2190

Order Name:
Apolipoprotein A1

 
 
Clinical Information:
Lipids that are synthesized in the intestine or liver need to be transported to tissues and organs for their varied metabolic functions. Given the hydrophobic nature of the neutral fats, triglycerides, and cholesterol esters, lipid transport and delivery via plasma would not be possible without some form of hydrophilic adaptation.
Lipids are transported by means of a series of micellar structures known as lipoproteins that consist of an outer monolayer of protein (apolipoprotein), polar lipids, and an inner core of neutral lipids.

Apolipoprotein A-I (ApoA-I) is synthesized in both the liver and intestine, while ApoA-II synthesis appears to occur only in the liver. ApoA-I and ApoA-II are the major apolipoproteins found in HDL, with small amounts
found in chylomicrons. Approximately 50% of HDL mass is protein, with ApoA-I and ApoA-II constituting approximately 90% of the lipoprotein fraction. The ratio of A-I to A-II is roughly 3:1. On average, ApoA-I levels
are higher in women than in men, whereas ApoA-II levels are similar.

Lipoprotein particles that contain only ApoA-I appear to stimulate cholesterol efflux (movement of cholesterol from extrahepatic tissues to the liver for disposal). ApoA-I also has a role in the activation of LCAT
(lecithin-cholesterol acyltransferase).

Measurement of ApoA-I is useful in predicting patients with high risk of coronary artery disease (CAD). Levels of ApoA-I are inversely correlated with the risk of premature CAD. The relative proportion of ApoB, a major component of VLDL and LDL, to ApoA is effective in differentiating individuals with or without ischemic heart disease. An increased ApoB/ApoA ratio at a young age is potentially a marker for CAD.

Elevated ApoA-I levels are seen in familial hyper-α-lipoproteinemia and weight reduction. Decreased levels are associated with various forms of familial and non-familial hypo-α-lipoproteinemia, Tangier disease, premature CAD, hypertriglyceridemia, uncontrolled diabetes, hepatocellular disorders, cholestasis, nephrotic syndrome, and chronic renal failure.
 
Reference Value:
Age (Year) Male (mg/dL) Female (mg/dL)
0 - 1 year 61 - 164 59 - 169
>1 - 12 years 93 - 172 86 - 179
>12 - 60 years 95 - 186 101 - 223
>60 years 73 - 186 91 - 224
 
Clinical Reference:
Manufacturer’s reagent package insert, Architect® Apolipoprotein A1, ABBOTT Laboratories, Abbott Park IL 60064 USA, November 2015.